Recent Headlines WACKER invests double-digit million euro amount in Biotechnology Center The WACKER Group is pooling its biotechnology research activities at its Munich site. The company is investing a double-digit million euro sum in the construction of a Biotechnology Center, which is scheduled to come on stream in 2024. With this investment, WACKER is strengthening its biotechnology business. r e k c a W © The WACKER Biotechnology Center will be built in Munich, at the site of the electrochemical industry consortium. . Laboratory and pilot-plant space is planned on some 2,000 square meters, spread over three floors. This will provide space for around 90 employees. Research will focus on processes for the production of biopharmaceuticals and on the fermentative production of ingredients for food and dietary supplements. By bundling biotechnological research and development under one roof, the efficiency of research work is to be improved. "With the WACKER Biotechnology Center, we are pooling and intensifying our biotech research activities. The additional capacity will accelerate the growth of our Life Science division," says WACKER CEO Christian Hartel, commenting on the construction project. As part of its growth strategy, the company plans to significantly increase investments in its biotechnology business in the coming years and expand its product portfolio through innovations, partnerships and acquisitions. Amgen theme island at the Deutsches Museum in Munich The Deutsches Museum in Munich, one of the world's largest science and technology museums, is opening many modernized museum areas following a renovation. The theme island of the biotechnology company Amgen, with two sites in Munich, which has already been on display at the museum since 2009, has also been updated. As a long-standing partner of the Deutsches Museum, Amgen's exhibits illustrate the medical benefits of biotechnology. New exhibition modules, including models, animations, graphics, videos and interactive elements, give visitors an insight into this key technology of the 21st century. n e g m A © Exhibition explains how biopharmaceuticals work and their benefits The first stop on Amgen's theme island explains the difference between synthetic chemical drugs, such as the classic headache tablet, and biopharmaceuticals, the best-known of which is insulin. The complex manufacturing processes of biopharmaceuticals, a key differentiator between the two categories of drugs, are also presented in an understandable way. Most of the Amgen exhibits explain the practical applications of biopharmaceuticals, for example, in cancer, cardiovascular disease and osteoporosis. Read more Bavarian Biotech News, July 2022 www.bio-m.org 7